William McKean
Medical Oncology · Salt Lake City, UTNPI 1548624828
Payments from drug & device makers
Across 463 payments — averaging $7260.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$1.1M
- Eli Lilly$908K
- Biontech SE$407K
- Stemline Therapeutics Inc.$269K
- Pfizer$219K
- Ipsen Pharma SAS$186K
- plus $230K from 15 others
Across 2 payments — averaging $635.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$1K
What the payments were for
- Consulting fees$1,69871%
- Food & beverage$68029%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 177 | $1,141,640 |
| Eli Lilly | 3 | $908,452 |
| Biontech SE | 98 | $407,365 |
| Stemline Therapeutics Inc. | 43 | $269,205 |
| Pfizer | 22 | $218,904 |
| Ipsen Pharma SAS | 53 | $186,242 |
| Modernatx, Inc. | 11 | $135,514 |
| AbbVie | 20 | $88,002 |
| Nuvation Bio Inc. | 3 | $4,182 |
| Daiichi Sankyo Inc. | 11 | $1,845 |
| Merck | 5 | $99 |
| EMD Serono, Inc. | 2 | $62 |
| Lilly USA, LLC | 3 | $49 |
| Genmab U.S., Inc. | 2 | $36 |
| Beigene USA, Inc. | 1 | $32 |
| Novartis | 1 | $27 |
| Genentech USA, Inc. | 1 | $26 |
| Array Biopharma Inc | 4 | $23 |
| Amgen | 1 | $21 |
| Bristol Myers Squibb | 1 | $20 |
| Deciphera Pharmaceuticals Inc. | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DATROWAY$485
How this compares
$3,361,766 in reported general payments places this provider in the 90th percentile of 43 medical oncology providers in Utah.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other medical oncology in Salt Lake City
- Wallace AkerleySalt Lake City$12.7M
- Stephan KendallSalt Lake City$10.2M
- Ignacio Garrido-LagunaSalt Lake City$8.8M
- Bradley HunterSalt Lake City$3.3M
- Ahmad HalwaniSalt Lake City$2.3M
- Paul ShamiSalt Lake City$1.5M
- Kenneth GrossmannSalt Lake City$931K
- Martha GlennSalt Lake City$768K
- Jeff RussellSalt Lake City$739K
- Mei WeiSalt Lake City$304K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.